Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business
Callisto Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Callisto Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2009-11-16 04:17:21 - Callisto Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Company-Profile/callisto-pha ..

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal (GI) disorders and diseases. The Company operates through its two subsidiaries, Synergy Pharmaceuticals Inc. and Callisto Research Labs, LLC. The Company’s lead drug candidates include SP-304, Atiprimod and L-Annamycin.

Callisto Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company. The company is focused on the development of novel therapeutics for the treatment of neuroendocrine cancer, acute leukemia and gastrointestinal disorders and diseases. The company’s pipeline products include: Atiprimod, L-Annamycin and SP-304. It

 

 

is headquartered at New York, United States.

The Callisto Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick ""one-stop-shop"" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser